Navigation Links
Top 200 Biopharmaceuticals Industry Report (Global)
Date:1/12/2012

NEW YORK, Jan. 12, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Top 200 Biopharmaceuticals Industry Report (Global)

http://www.reportlinker.com/p0572074/Top-200-Biopharmaceuticals-Industry-Report-Global.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharma

The Global Biopharmaceuticals Industry Report

Plimsoll Publishing Ltd.

This report is an in-depth financial evaluation of the Global Biopharmaceuticals Industry. Using the unique Plimsoll method of analysis, each of the top 200 Biopharmaceuticals Companies is individually assessed and ranked against each other and compared to industry averages. Using the most up-to-date financial information available, the two-page per company analysis provides detailed financial analysis for each organisation, including details of;

• Sales growth

• Trading stability

• Profitability

• Employee performance

• Level of debt

• Gearing ratio's

• Creditor Exposure

• Performance ratio's

• Overall financial rating

Results are shown in graphical, numeric and narrative forms, and all individual analysis are measured in both the company's own currency, and USD ($) for ease of use. These individual analyses highlight a company's success just as easily as it can emphasise its vulnerability.

Along with individual company information, this report also contains an assesment of the market, based on the companies analysed. This key information identifies;

• Best trading partners (based on commercial and financial strength)

• Sales growth (highest sales, growth rate, size of market based on the companies analysed, average growth)

• Profitability (Profit return on assets, pre-tax profit margins, industry average)

• Fastest growing companies (performance matrix)

Companies can change at an alarming rate in a very short space of time, so it is vital that you keep up-to-date with any changes to your market, and how those changes can affect you. This report can provide you with an in-depth look at your industry, highlight new market opportunities and provide important information to help develop accurate strategic business plans. Whether you wish to benchmark your own company's results, study the industry in more depth or have a vast array of industry intelligence at your disposal, this report is the ideal resource.

This extensive report is broken into two parts:

1. A complete financial assessment of the market, based on the companies analysed

2. An individual financial performance analysis of each company (2 pages per company)

Specific areas included in the market assessment include;

Section 1 - Best Trading Partners (based on commercial and financial strength)

1.1a – Best Trading Partners definition and industry top 5 list

1.1b – Performance matrix (Financial Strength Vs Sales Growth)

1.1c – List of Best Trading Partners in the industry

Section 2 - Sales & Market Performance

2.1 – Sales Growth

2.1a – 4 year trend analysis

2.1b – Industry Average Sales Growth

2.1c – Sales Growth Ranking Table

2.1d – Top 50 Companies ranked by Market Share

2.2 – Sales Return on Assets

2.2a – 4 year trend analysis

2.2b – Sales return on total assets

2.2c – Sales return on assets ranking table

2.2d – Top 50 companies' sales return on assets

Section 3 – Profitability

3.1 – Pre-tax profit margin

3.1a – Pre-tax profit margin 4 year trend analysis

3.1b – Industry Average pre-tax profit margin

3.1c – Pre-tax profit margin ranking table

3.1d – Top 50 companies actual pre-tax profit

3.2 - Pre-tax profit return on total assets

3.2a - Pre-tax profit return on total assets 4 year trend analysis

3.2b – Industry average pre-tax profit return on total assets

3.2c – Pre-tax profit return on total assets ranking table

3.3 - Profitability

3.3a – Profitability industry average

4. 0 – How to Use

5.0 – Individual Company Analysis

The individual company assessment gives a complete financial picture of each company listed, including a narrative summary of the analysis. One of our key indicators is the Plimsoll Chart which combines several performance figures to give an overall measurement of the financial strength of any company. The Plimsoll chart is complied through the analysis of several different areas, including;

Sales Growth, Trading Stability, Profitability, Working Capital, Gearing and Immediate Liquidity

As all measurements are standardised, in one report you can quickly compare like with like for every major company in your industry. The accounts of each company appear in its own currency and US$ to allow comparison.

Each individual company analysis includes:

• A full four year financial assessment, Debtor days analysis, Latest sales/profitability rankings.

• Employee Performance Analysis, Comparisons against industry average.

• Overall company financial rating as read in the Plimsoll Chart, Industry ranking matrix.

• Company analysis written summary.

Other information in the report includes;

• Details of the Plimsoll Model

• Definition of Terms

• List of Shareholders

• Global Index by region

• Ranking Analysis by sales/profits

• Companies considered but not included

• Index of companies

To order this report:

Biopharmaceutical Industry: Top 200 Biopharmaceuticals Industry Report (Global)

More  Market Research Report

Check our  Industry Analysis and Insights

CONTACT:
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
2. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
3. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
4. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
5. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
7. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
8. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
9. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
10. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
11. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
(Date:9/19/2017)... ZirMed Inc ., a recognized leader in cloud-based revenue cycle ... ranked #1 by its users for the seventh consecutive year ... ZirMed was recognized as the top-ranked end-to-end revenue cycle management ... 200 beds and holds one of the longest #1 ranking ... ...
(Date:9/12/2017)... LAKES, N.J. , Sept. 12, 2017  Consumer reviews on ... Embrace Hearing as the number one company for hearing aids, ... ReSound™ and fifteen other brands. ... Embrace Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that provides ...
Breaking Medicine Technology:
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
(Date:10/12/2017)... ... , ... The American College of Medical Informatics (ACMI) will present the 2017 ... Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is ... pioneer in the field of medical informatics, this prestigious award is presented to an ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in healthcare ... Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during ... , The annual award competition recognizes editorial and design excellence across a range of ...
Breaking Medicine News(10 mins):